Literature DB >> 30385602

Clofazimine does not lead to significant QT interval prolongation: a multicentre study.

Sanne M H Zweijpfenning1, Hester van Groningen1, Jakko van Ingen2, Cecile Magis-Escurra1, Martin J Boeree1, Dirk Wagner3, Hannelore Bax4, Claire Andrejak5, Reinier Wener6, Ananna Rahman7, Heinke Kunst8, Natalie Lorent9, Marc A Brouwer10, Wouter Hoefsloot1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30385602     DOI： 10.1183/13993003.01386-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.

Authors:  Fumiya Watanabe; Koji Furuuchi; Kazuhiko Hanada; Keiji Fujiwara; Fumiko Uesugi; Miyako Hiramatsu; Takashi Yoshiyama; Yuji Shiraishi; Atsuyuki Kurashima; Ken Ohta; Kozo Morimoto
Journal:  Antimicrob Agents Chemother       Date:  2022-07-07       Impact factor: 5.938

2.  Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.

Authors:  Fangchao Liu; Jingtao Gao; Mengqiu Gao; Yuhong Liu; Wei Shu; Li Xie; Yuxian Sun; Lijie Zhang; Liang Li; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2022-09-01       Impact factor: 5.938

Review 3.  Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians.

Authors:  Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid
Journal:  Open Forum Infect Dis       Date:  2022-06-15       Impact factor: 4.423

4.  Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis.

Authors:  Lénaïg Tanneau; Elin M Svensson; Stefaan Rossenu; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.